Hattori Fumihiko, Miura Hiroki, Sugata Ken, Yoshikawa Akiko, Ihira Masaru, Yahata Yuichiro, Kamiya Hajime, Tanaka-Taya Keiko, Yoshikawa Tetsushi
Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan.
Graduate School of Health Sciences, Fujita Health University, Toyoake, Aichi 470-1192, Japan.
Vaccine. 2017 Sep 5;35(37):4936-4941. doi: 10.1016/j.vaccine.2017.07.090. Epub 2017 Aug 4.
Matched case control study was conducted to elucidate the effectiveness of the Oka/Biken vaccine immediately after implementation of the universal immunization program in Japan.
Cases were laboratory confirmed varicella patient under 15years of age diagnosed at 14 designated pediatric clinics between September 2015 and September 2016. Controls were selected from patients who visited the same practice for different reasons as the varicella case within 2weeks. Swab samples were collected from varicella suspected patients and molecular diagnostic assays were used to confirm varicella cases. Matched odds ratio were used to calculate vaccine effectiveness (VE).
Varicella zoster virus DNA was detected in 183 (81.3%) of 225 suspected cases. One sample was excluded because it was positive for the Oka vaccine strain (182/225, 80.9%). Three hundred twenty-three control subjects were enrolled. The effectiveness of 1 dose of the Oka/Biken vaccine compared with no vaccine was 76.7% (95% confidence interval [CI]: 58.6-86.9%; P<0.001). The effectiveness of 2 doses of the Oka/Biken vaccine was 94.2% (95% CI: 85.7-97.6%; P<0.001). After adjusting for potential confounding effects, the adjusted VE of 1 and 2 doses of varicella vaccine were 76.9% (95% CI: 58.1-87.3%; P<0.001) and 94.7% (95% CI: 86.0-98.0%; P<0.001), respectively.
VE of one dose of Oka/Biken varicella vaccine was insufficient to control varicella. Therefore, two doses of Oka/Biken varicella vaccine is significant for controlling varicella in Japan.
开展配对病例对照研究,以阐明日本实施普遍免疫规划后,冈田/比肯疫苗的有效性。
病例为2015年9月至2016年9月期间在14家指定儿科诊所确诊的15岁以下实验室确诊水痘患者。对照从在2周内因不同原因前往同一医疗机构就诊的患者中选取,这些患者与水痘病例情况相同。从疑似水痘患者中采集拭子样本,并使用分子诊断检测来确诊水痘病例。采用配对比值比计算疫苗有效性(VE)。
225例疑似病例中有183例(81.3%)检测到水痘带状疱疹病毒DNA。1份样本因对冈田疫苗株呈阳性而被排除(182/225,80.9%)。共纳入323名对照受试者。与未接种疫苗相比,1剂冈田/比肯疫苗的有效性为76.7%(95%置信区间[CI]:58.6 - 86.9%;P<0.001)。2剂冈田/比肯疫苗的有效性为94.2%(95%CI:85.7 - 97.6%;P<0.001)。在调整潜在混杂效应后,1剂和2剂水痘疫苗的调整后VE分别为76.9%(95%CI:58.1 - 87.3%;P<0.001)和94.7%(9%CI:86.0 - 98.0%;P<0.001)。
1剂冈田/比肯水痘疫苗不足以控制水痘。因此,2剂冈田/比肯水痘疫苗对日本控制水痘具有重要意义。